FOA Title: 
NCI Request for Information (RFI): Input on Development of an NCI Cancer Biomarker Data Aggregator
Grant Type: 
NOT-CA-18-095
Primary IC: 
NCI
Release Date: 
Jul 23 2018
Expiration Date: 
N/A
AC Source: 
N/A
Purpose: 
NCI Request Information RFI): Input Development an NCI Cancer Biomarker Data Aggregator Notice Number: NOT-CA-18-095 Key Dates Release Date: July 23, 2018 Response Date: October 20, 2018 Related Announcements None Issued National Cancer Institute NCI) Purpose Request Information RFI) seeks public input opinions the proposed development a Cancer Biomarker Data Aggregator CBAG), federated data system a crucial clinically-oriented node the NCI’s Cancer Research Data Commons CRDC). Background Powered recent advancements high throughput technologies, biomarker research considered of most data-intensive areas cancer research. biomarker development process involves aggregation massive amounts complex, multi-modal data such gene expression, cell types, imaging, protein counts used conjunction clinical information prior knowledge. find links between potential biomarkers disease phenotypes, multitude analytical approaches data modeling machine learning, model selection, simulation techniques, performance analysis been developed employed. Nonetheless, despite considerable success the preclinical setting, majority biomarker-based tests yet demonstrate clinical validity clinical utility, especially the area risk assessment, early detection, diagnosis cancer, where bar test performance set increasingly high. of fundamental challenges biomarker discovery validation the lack an efficient data infrastructure. Such infrastructure facilitate annotation well the secondary of high-value datasets biomarker selection new indications, validation meta-analysis, benchmarking selection algorithms, post-market test surveillance, and, ultimately, assembling evidence jigsaw clinical utility specific biomarkers tests patient populations.        Recently, NCI initiated development the Cancer Research Data Commons CRDC) facilitate access essential datasets, computing resources, tools. Using experience gained these efforts, NCI now proposing pilot Cancer Biomarker Data Aggregator CBAG) a node the CRDC test different ways accelerate biomarker research its translation clinically useful tests. primary goal the proposed node be provide streamlined access relevant tools, services, curated information biomarkers potential clinical utility risk assessment, early detection, diagnosis cancer. this capacity, CBAG complement CRDC nodes well commercial databases such BiomarkerBase Gobiom, are focused chiefly biomarkers treatment response therapeutic target discovery. ensure the pilot CBAG support needs the cancer research community advance biomarker discovery development, wish engage potential CBAG users academia, industry, government, private organizations. Information Requested NCI interested soliciting suggestions opinions regarding scope, cases, clinical needs, priority areas the pilot CBAG should focus to accelerate development biomarkers tests risk assessment early detection cancer. Areas interest include are limited the following: cases such leveraging data longitudinal studies containing biomarkers putative clinical utility hereditary, familial, sporadic cancers be included the pilot node Examples secondary data uses such selection biomarkers new indications, model selection, development, comparison, well training education Challenges related sharing, harmonization, curation biomarker data metadata Challenges related mining integrating biomarker data prior knowledge the literature, free-text clinicians notes, public knowledgebases   Inclusion/exclusion criteria pilot data collections such data annotation quality, study design, sample size, pre-diagnostic specimens, patient-level metadata Incentives biomarker data sharing, annotation, standard adoption including crowdsourcing competitions, data citations usage statistics, open-data badges papers, tokens services access other datasets Incentives collaborative analytics annotation using machine learning, Natural Language Processing, statistical modeling, simulation techniques, performance analysis tools biomarkers tests Submitting Response responses must submitted to natalie.abrams@nih.gov October 20, 2018. Please include Notice number/RFI number here the subject line. Please as specific possible, provide examples data support suggestions, prioritize comments, include new ideas relevant the question being asked. Please not include any proprietary, classified, confidential, sensitive information your response. NIH use information submitted response this RFI its discretion will provide comments any responder's submission. NIH use information gathered this RFI inform development future funding opportunity announcements in any resultant solicitations. RFI for information planning purposes only should be construed a solicitation as obligation the part the Federal Government, National Institutes Health NIH), individual NIH Institutes Centers. NIH does intend make any awards based responses this RFI to otherwise pay preparation any information submitted for Government's of such information. basis claims against U.S. Government shall arise a result a response this request information from Government’s of such information. Responses be aggregated may shared publicly. References 1] NCI Cancer Research Data Commons CRDC)  2] NCI Genomic Data Commons GDC) 3] NIH Strategic Plan Data Science 4] NIH Genomic Data Sharing Policy NOT-OD-14-124) 5] NIH Notice Use Cloud Computing Services Storage Analysis Controlled-Access Data Subject the NIH Genomic Data Sharing Policy NOT-OD-15-086) 6] NCI Cancer Immunologic Data Commons RFA-CA-17-006) 7] Input Development the NCI Imaging Data Commons NOT-CA-18-060) 8] NCI Strategies Matching Patients Clinical Trials NOT-CA-18-063) 9] NIH Biomedical Data Translator NOT-TR-17-023) 10] Secondary Analysis Integration Existing Data Elucidate Genetic Architecture Cancer Risk Related Outcomes PA-17-239) Inquiries Please direct inquiries to: general inquiries regarding early detection risk assessment cancer, please contact: Sudhir Srivastava, MPH, PhD National Cancer Institute Telephone: 240-276-7028 Email: srivasts@mail.nih.gov inquiries specifically related this RFI, contact: Natalie Abrams, PhD National Cancer Institute Telephone: 240-276-5506 Email: natalie.abrams@nih.gov